Treatment of HIV-Infected Subjects with Buttock Lipoatrophy Using Stabilized Hyaluronic Acid Gel
Related Experiment Video
Updated: Apr 5, 2026
Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration
Published on: September 29, 2018
Olivier Claude1, Romain Bosc1, Fréderic Pigneur1
1Department of Plastic and Reconstructive Surgery, Hospital Henri Mondor, Créteil, France; Department of Reconstructive and Esthetic Plastic Surgery, Hospital Européen Georges Pompidou, Paris, France; and AP-HP, Groupe Henri-Mondor Albert-Chenevier, Imagerie Medicale, Créteil, France.
Abstract:
This prospective study explored effectiveness and safety of Macrolane VRF30 for treatment of buttock lipoatrophy in HIV-infected subjects. Ten subjects who were unable to sit for more than 30 minutes because of pain were injected with a mean of 276 mL and followed for 18 months. The pain score was reduced, and the time that subjects could sit was increased at least up to 9 months post treatment. There was no local displacement of gel. Five mild adverse events occurred; all related to the injection procedure. This pilot study indicates that Macrolane treatment of buttock lipoatrophy is a promising, well-tolerated method that reduces pain at sitting and improves buttock appearance.
